Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, NUTRA PHARMA CORP. reported revenue of $0M, up 4.6% year over year. Operating margin was -567.7% and net margin -794.8%, on a free-cash-flow margin of -461.9% with capital expenditure at 10.1% of revenue. Every figure is computed directly from NPHC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -567.7% | -794.8% |
| FY2024 | $0M | -356.6% | -522.0% |
| FY2023 | $0M | -431.5% | -677.8% |
| FY2022 | $0M | -1308.2% | 5608.3% |
| FY2021 | $0M | -2034.5% | -13399.0% |
How does NPHC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.